Helius Med Technologies Inc Stock Price, News & Analysis

Helius Medical Technologies (Nasdaq:HSDT) announced the addition of Neurology Center of New England (NCNE) to its Therapeutic Experience Program (TEP), aiming to assess the adherence to PoNS therapy for gait improvement in Multiple Sclerosis (MS) patients. NCNE will contribute to a multi-center observational trial, enhancing understanding of PoNS therapy's real-world impact on MS treatment. The study will involve 50-60 participants at various Centers of Excellence, with enrollment beginning in Q4 2022 and continuing into 2023.

Helius Medical Technologies (NASDAQ: HSDT) has extended its Patient Therapy Access Program (PTAP) until June 30, 2023, allowing more Americans with multiple sclerosis (MS) to access PoNS Therapy™ at a reduced cost. This initiative, which began in June 2022, subsidizes therapy for those with a prescription and medical necessity letter. The PoNS device stimulates neural pathways to improve gait. Helius aims to enhance accessibility to this innovative neurotechnology, focusing on improving the mobility and quality of life for individuals with MS.

Helius Medical Technologies (NASDAQ: HSDT) has launched a new e-commerce site in partnership with UpScript to improve accessibility for Americans with gait issues. The Portable Neuromodulation Stimulator (PoNS®) device is now available online, allowing patients to receive it directly at home. This telehealth initiative is expected to streamline treatment for multiple sclerosis (MS) patients, enhancing their journey toward better mobility while still requiring physical therapist involvement.

Helius Medical Technologies (HSDT) announced on December 30, 2022, that its independent directors approved an equity award under its 2021 Inducement Plan for a new employee. The award includes an option to purchase 50,000 shares at an exercise price of $0.215 per share, the closing price on the grant date. The option vests over four years and has a ten-year term. Helius specializes in neurotechnology, aiming to enhance neurologic wellness through devices like the Portable Neuromodulation Stimulator (PoNS), which addresses gait deficits in multiple sclerosis.

Helius Medical Technologies (HSDT) reported a strong Q3 2022 with total revenue soaring by 80% to $196,000 compared to $109,000 in Q3 2021. This is attributed to the commercial availability of PoNS Therapy, which has gained positive market traction. The company raised $18 million in a public offering, providing $16.7 million in cash reserves for operations through 2023. Operating loss increased to $4.9 million, but net loss improved to $1 million from $4.7 million year-over-year, indicating a shift towards operational stability.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) has announced the addition of the MGH Institute of Health Professions as the fourth Center of Excellence in its Therapeutic Experience Program (TEP). This multi-center, open-label observational trial aims to assess the adherence to Portable Neuromodulation Stimulator (PoNS) therapy among multiple sclerosis (MS) patients. Enrollment is expected to start in Q4 2022, involving 50-60 participants across 10-12 centers. The study seeks to evaluate the relationship between treatment adherence and gait improvement in MS.

Helius Medical Technologies (Nasdaq: HSDT) announced the addition of Oregon Health & Science University to its Therapeutic Experience Program, aiming to evaluate the effects of PoNS therapy for gait improvement in patients with multiple sclerosis (MS). The study is a multi-center, open-label trial to assess adherence to the PoNS device combined with physical therapy. Enrollment is expected to start in Q4 2022, targeting 50-60 MS patients across 10-12 Centers of Excellence in the U.S. Key endpoints include maintenance of gait improvement and overall functional outcomes.

Helius Medical Technologies will showcase its innovative Portable Neuromodulation Stimulator (PoNS®) at the ACRM Conference in Chicago from November 8-11. Visitors to booth 512 can explore how PoNS aids those with multiple sclerosis (MS) in improving gait deficiencies. The device uses electrical impulses through the tongue to stimulate neural pathways, enhancing mobility. Physical therapists can register for free online training to maximize the effectiveness of PoNS therapy. Helius is committed to supporting MS patients as 70% report mobility challenges.

Helius Medical Technologies (NASDAQ: HSDT) will release its Q3 2022 financial results on November 14, 2022, before the market opens. Following this, CEO Dane C. Andreeff and CFO Jeffrey S. Mathiesen will host a conference call at 8:30 a.m. ET to discuss the results and provide insights into the commercialization of PoNS®. The call can be accessed via registration, and a webcast will be archived for later viewing on the company’s investor relations website.